Reversible Heart Failure after Bortezomib Treatment in a Patient with Multiple Myeloma / 대한내과학회지
Korean Journal of Medicine
;
: 459-463, 2015.
Article
in Korean
| WPRIM
| ID: wpr-194217
ABSTRACT
Bortezomib (Velcade(R)) came into the spotlight as a target therapy for multiple myeloma. It acts through reversible inhibition of intracellular proteasomes, which triggers apoptosis, with relative selectivity for malignant cells. It has been hypothesized that the accumulation of damaged proteins in myocytes impairs cardiac function. Cardiotoxicity is a rare side effect of bortezomib treatment. We report a case of reversible systolic heart failure that probably occurred after bortezomib treatment in a patient with multiple myeloma. Patients being treated with bortezomib who have previously had cardiac comorbidities should undergo routine cardiac monitoring.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Comorbidity
/
Apoptosis
/
Muscle Cells
/
Heart Failure, Systolic
/
Bortezomib
/
Heart Failure
/
Multiple Myeloma
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2015
Type:
Article
Similar
MEDLINE
...
LILACS
LIS